113 related articles for article (PubMed ID: 15759101)
1. Tyrosinaemia type I--de novo mutation in liver tissue suppressing an inborn splicing defect.
Bliksrud YT; Brodtkorb E; Andresen PA; van den Berg IE; Kvittingen EA
J Mol Med (Berl); 2005 May; 83(5):406-10. PubMed ID: 15759101
[TBL] [Abstract][Full Text] [Related]
2. Self-induced correction of the genetic defect in tyrosinemia type I.
Kvittingen EA; Rootwelt H; Berger R; Brandtzaeg P
J Clin Invest; 1994 Oct; 94(4):1657-61. PubMed ID: 7929843
[TBL] [Abstract][Full Text] [Related]
3. The somatic FAH C.1061C>A change counteracts the frequent FAH c.1062+5G>A mutation and permits U1snRNA-based splicing correction.
Scalet D; Sacchetto C; Bernardi F; Pinotti M; van de Graaf SFJ; Balestra D
J Hum Genet; 2018 May; 63(5):683-686. PubMed ID: 29497141
[TBL] [Abstract][Full Text] [Related]
4. Hereditary tyrosinaemia type I in Norway: incidence and three novel small deletions in the fumarylacetoacetase gene.
Bliksrud YT; Brodtkorb E; Backe PH; Woldseth B; Rootwelt H
Scand J Clin Lab Invest; 2012 Sep; 72(5):369-73. PubMed ID: 22554029
[TBL] [Abstract][Full Text] [Related]
5. Point mutations in the murine fumarylacetoacetate hydrolase gene: Animal models for the human genetic disorder hereditary tyrosinemia type 1.
Aponte JL; Sega GA; Hauser LJ; Dhar MS; Withrow CM; Carpenter DA; Rinchik EM; Culiat CT; Johnson DK
Proc Natl Acad Sci U S A; 2001 Jan; 98(2):641-5. PubMed ID: 11209059
[TBL] [Abstract][Full Text] [Related]
6. A missense mutation (Q279R) in the fumarylacetoacetate hydrolase gene, responsible for hereditary tyrosinemia, acts as a splicing mutation.
Dreumont N; Poudrier JA; Bergeron A; Levy HL; Baklouti F; Tanguay RM
BMC Genet; 2001; 2():9. PubMed ID: 11476670
[TBL] [Abstract][Full Text] [Related]
7. Identification of a combined missense/splice-site mutation in FAH causing tyrosinemia type 1.
Haghighi-Kakhki H; Rezazadeh J; Ahmadi-Shadmehri A
J Pediatr Endocrinol Metab; 2014 Jul; 27(7-8):795-8. PubMed ID: 24756054
[TBL] [Abstract][Full Text] [Related]
8. Frequent mutation reversion inversely correlates with clinical severity in a genetic liver disease, hereditary tyrosinemia.
Demers SI; Russo P; Lettre F; Tanguay RM
Hum Pathol; 2003 Dec; 34(12):1313-20. PubMed ID: 14691918
[TBL] [Abstract][Full Text] [Related]
9. Fumarylacetoacetase mutations in tyrosinaemia type I.
Rootwelt H; Høie K; Berger R; Kvittingen EA
Hum Mutat; 1996; 7(3):239-43. PubMed ID: 8829657
[TBL] [Abstract][Full Text] [Related]
10. [Mutation analysis of FAH gene in patients with tyrosinemia type 1].
Dou LM; Fang LJ; Wang XH; Lu W; Chen R; Li LT; Zhao J; Wang JS
Zhonghua Er Ke Za Zhi; 2013 Apr; 51(4):302-7. PubMed ID: 23927806
[TBL] [Abstract][Full Text] [Related]
11. Heterozygosity for an exon 12 splicing mutation and a W234G missense mutation in an American child with chronic tyrosinemia type 1.
Hahn SH; Krasnewich D; Brantly M; Kvittingen EA; Gahl WA
Hum Mutat; 1995; 6(1):66-73. PubMed ID: 7550234
[TBL] [Abstract][Full Text] [Related]
12. Hereditary tyrosinemia type 1: novel missense, nonsense and splice consensus mutations in the human fumarylacetoacetate hydrolase gene; variability of the genotype-phenotype relationship.
Ploos van Amstel JK; Bergman AJ; van Beurden EA; Roijers JF; Peelen T; van den Berg IE; Poll-The BT; Kvittingen EA; Berger R
Hum Genet; 1996 Jan; 97(1):51-9. PubMed ID: 8557261
[TBL] [Abstract][Full Text] [Related]
13. Identification of a stop mutation in five Finnish patients suffering from hereditary tyrosinemia type I.
St-Louis M; Leclerc B; Laine J; Salo MK; Holmberg C; Tanguay RM
Hum Mol Genet; 1994 Jan; 3(1):69-72. PubMed ID: 8162054
[TBL] [Abstract][Full Text] [Related]
14. Hereditary tyrosinemia type I. Self-induced correction of the fumarylacetoacetase defect.
Kvittingen EA; Rootwelt H; Brandtzaeg P; Bergan A; Berger R
J Clin Invest; 1993 Apr; 91(4):1816-21. PubMed ID: 8473520
[TBL] [Abstract][Full Text] [Related]
15. Direct sequencing of FAH gene in Pakistani tyrosinemia type 1 families reveals a novel mutation.
Ijaz S; Zahoor MY; Imran M; Afzal S; Bhinder MA; Ullah I; Cheema HA; Ramzan K; Shehzad W
J Pediatr Endocrinol Metab; 2016 Mar; 29(3):327-32. PubMed ID: 26565546
[TBL] [Abstract][Full Text] [Related]
16. Gene symbol: FAH. Disease: tyrosinaemia 1.
Arranz A; Rigante D; Antuzzi D; Riudor E
Hum Genet; 2005 Dec; 118(3-4):537. PubMed ID: 16521249
[No Abstract] [Full Text] [Related]
17. Different clinical forms of hereditary tyrosinemia (type I) in patients with identical genotypes.
Poudrier J; Lettre F; Scriver CR; Larochelle J; Tanguay RM
Mol Genet Metab; 1998 Jun; 64(2):119-25. PubMed ID: 9705236
[TBL] [Abstract][Full Text] [Related]
18. Adenine base editing in an adult mouse model of tyrosinaemia.
Song CQ; Jiang T; Richter M; Rhym LH; Koblan LW; Zafra MP; Schatoff EM; Doman JL; Cao Y; Dow LE; Zhu LJ; Anderson DG; Liu DR; Yin H; Xue W
Nat Biomed Eng; 2020 Jan; 4(1):125-130. PubMed ID: 31740768
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the human fumarylacetoacetate hydrolase gene and identification of a missense mutation abolishing enzymatic activity.
Labelle Y; Phaneuf D; Leclerc B; Tanguay RM
Hum Mol Genet; 1993 Jul; 2(7):941-6. PubMed ID: 8364576
[TBL] [Abstract][Full Text] [Related]
20. Splicing mutations, mainly IVS6-1(G>T), account for 70% of fumarylacetoacetate hydrolase (FAH) gene alterations, including 7 novel mutations, in a survey of 29 tyrosinemia type I patients.
Arranz JA; Piñol F; Kozak L; Pérez-Cerdá C; Cormand B; Ugarte M; Riudor E
Hum Mutat; 2002 Sep; 20(3):180-8. PubMed ID: 12203990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]